Shilajit And Blood Pressure Medicine: What The One Human Study Shows

Last reviewed: October 6, 2026 · By Dr. Ekta Gupta · Evidence tier labels apply on every claim (see our editorial policy)

Shilajit and blood pressure medicine is a combination that deserves careful, evidence-based scrutiny — not enthusiasm. To be direct from the outset: there is no clinical trial showing that shilajit lowers blood pressure in hypertensive humans, and it should never be used as a replacement for prescribed antihypertensive medication. What does exist is a single human study examining how shilajit interacts with the cardiovascular system, plus a small body of animal and mechanistic research. This article unpacks what that evidence actually shows, where the uncertainty lies, and what anyone managing blood pressure should know before adding shilajit to their routine.

What Shilajit Is — And What It Is Not

Shilajit is a blackish-brown exudate that seeps from high-altitude rock formations across the Himalayas, Altai, and Caucasus mountains. It forms over centuries as plant matter compresses under geological pressure, yielding a matrix of fulvic acid, humic substances, dibenzo-alpha-pyrones, and more than 80 trace minerals. Ayurvedic medicine has used it for millennia as an adaptogen and rejuvenator — a broad category that says little about its specific pharmacological actions.

It is not a cardiovascular drug. It has no approved indication for blood pressure management in any country. Anyone reading headlines suggesting otherwise should verify those claims against the actual study designs — most are animal models or in-vitro experiments that cannot be directly extrapolated to human outcomes. For a broader orientation to the compound, the What is Shilajit? Benefits, Uses & Purity Guide covers its origins and primary documented uses in more depth.

That context matters because the cardiovascular system is a YMYL (your money or your life) domain. Stopping or reducing antihypertensive medication without medical supervision can cause dangerous rebound hypertension, stroke, or heart attack. Nothing in the research reviewed here changes that calculus.

Important safety notice: If you are currently taking blood pressure medication — including ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, or diuretics — consult your prescribing physician before adding any supplement, including shilajit. This article is educational, not medical advice.

The One Human Study: What the Data Actually Show

The cardiovascular literature on shilajit is thin when it comes to human trials. The most frequently cited human-adjacent work relates to safety and general physiological effects rather than blood pressure endpoints specifically. Stohs 2014 (Phytother Res) published a comprehensive safety and efficacy review that remains the most rigorous synthesis of human-relevant data available. [Meta-analysis / Review]

That review found that purified shilajit administered at doses of 200–500 mg per day to healthy adults was generally well tolerated, with no clinically significant changes in blood pressure, heart rate, or serum electrolytes reported across the trials it examined. The key word is healthy. Study participants were not hypertensive, were not on antihypertensive drugs, and were not specifically monitored for blood pressure response as a primary endpoint. Extrapolating "no change in healthy volunteers" to "safe for hypertensive patients on medication" is a logical gap that the data do not bridge.

A more recent placebo-controlled trial — Yadav 2026 (Cureus) — examined TruBlk™ shilajit resin on physical performance markers over eight weeks. [RCT] Blood pressure was among the safety markers tracked. Again, no adverse changes were observed in a healthy, physically active population. But the trial was not designed to test shilajit's effect on hypertension, and participants were not on concurrent antihypertensive medications. The honest reading: shilajit does not appear to raise blood pressure in healthy people, but there is no human RCT testing it specifically in hypertensive individuals or alongside blood pressure drugs.

Animal and Mechanistic Evidence: Cardioprotection, Not Pressure Control

The Mumie Cardioprotection Study

The most directly cardiovascular piece of non-human research is Joukar 2014 (Cardiovasc Toxicol), which investigated the cardioprotective potential of mumie (shilajit) in a rat model of experimentally induced myocardial injury. [Animal model] Rats pretreated with shilajit showed attenuated cardiac enzyme markers (creatine kinase, lactate dehydrogenase) and reduced electrocardiographic abnormalities compared to controls after injury was induced. The proposed mechanisms include antioxidant activity, mitochondrial protection, and reduction of oxidative stress in cardiac tissue.

This is meaningful preliminary data — but it describes protection against acute myocardial damage, not blood pressure regulation. The two are related but distinct physiological processes. Cardioprotection after ischemic injury operates through different pathways than chronic management of systolic or diastolic pressure.

Fulvic Acid and Vascular Mechanisms

Fulvic acid — the primary bioactive fraction in quality shilajit — has been studied for its antioxidant and anti-inflammatory properties. [Mechanism] Carrasco-Gallardo 2012 (Int J Alzheimers Dis) describes fulvic acid's capacity to chelate metal ions, modulate inflammatory cascades, and cross biological membranes efficiently. Chronic low-grade inflammation and oxidative stress are recognized contributors to endothelial dysfunction and hypertension, so there is a plausible mechanistic thread. But mechanism ≠ clinical outcome. A compound that reduces a contributing factor in cell culture does not necessarily reduce blood pressure in a medicated human patient in a predictable or safe way.

If you are interested in the fulvic acid content and how it varies by source and preparation, the Fulvic Acid Shilajit: 76% Eurofins Lab-Tested Quality article covers purity testing and what the numbers mean in practice.

Drug Interaction Risk: The Real Gap in the Evidence

The most pressing practical question for anyone managing hypertension is not whether shilajit has cardiovascular effects in isolation — it is whether shilajit interacts with antihypertensive medications. This is where the evidence gap is most acute.

No published human study has examined shilajit co-administered with:

• ACE inhibitors (e.g., lisinopril, ramipril)
• Angiotensin receptor blockers (e.g., losartan, valsartan)
• Beta-blockers (e.g., metoprolol, atenolol)
• Calcium channel blockers (e.g., amlodipine, diltiazem)
• Thiazide or loop diuretics (e.g., hydrochlorothiazide, furosemide)

Fulvic acid's known ion-chelation activity raises a theoretical concern: it could potentially alter the absorption kinetics of mineral-dependent drugs or interact with the trace-mineral balance that some diuretics already perturb. This is not a documented interaction — it is a mechanism-based caution. [Mechanism] The distinction matters, but so does the absence of safety data. "Not proven harmful" is not the same as "proven safe."

A separate concern involves shilajit's reported effects on iron metabolism. Patients on certain cardiac medications who also have iron-related conditions (hemochromatosis, for example) should discuss supplementation with their physician before starting. The Shilajit Side Effects: What to Know Before Use article covers these individual risk factors in structured detail.

Shilajit, Blood Pressure, and Women: A Specific Consideration

Hypertension in women has a distinct epidemiological and pharmacological profile. Women tend to develop hypertension at older ages than men, experience it more acutely post-menopause due to declining estrogen's vasodilatory effects, and are more likely to experience adverse drug reactions from antihypertensive medications. These factors make the question of shilajit and blood pressure medicine particularly relevant for a female demographic.

Shilajit's hormonal effects in women are incompletely studied. The testosterone-focused RCT by Pandit 2016 (Andrologia) enrolled only men. [RCT] Whether shilajit influences estrogen, progesterone, or the renin-angiotensin-aldosterone axis in women — which is directly relevant to blood pressure — is an open question. Some women report benefits in energy and cycle regularity from shilajit, but these are largely anecdotal. [Anecdotal]

Women who are pregnant, postmenopausal, or on hormone therapy should be especially cautious. The Shilajit Benefits for Women: Skin, Energy & Hormonal Balance guide takes a nuanced look at what is and is not supported by evidence for female users specifically.

Clinical note for women: If you are postmenopausal and managing blood pressure, or if you are on hormone replacement therapy alongside antihypertensives, the potential for multi-system interactions is higher. Please discuss any supplement additions with your cardiologist or GP before starting.

Dosage, Quality, and Timing Considerations

Standard Dosage Ranges

Across the human studies reviewed, shilajit doses ranged from 200 mg to 500 mg per day of purified resin or standardized extract. The safety profile at these doses in healthy adults appears acceptable, with no clinically significant cardiovascular changes documented. Doses above 500 mg daily have not been studied in controlled human trials, and higher doses are not supported by better outcomes in the available literature.

Resin form is generally considered the most bioavailable and the easiest to dose precisely — though this depends on product purity. The Shilajit Resin vs Powder vs Capsules: Best Form? comparison breaks down the trade-offs by format. For a practical guide to timing and preparation, the How to Use Shilajit: Dosage, Best Time & Prep Guide covers the specifics without overclaiming.

Heavy Metal Contamination Risk

One underappreciated risk in the shilajit-heart health conversation is contamination. Kamgar 2025 (BMC Chem) quantified thallium levels in shilajit samples and supplements, finding that some commercial products contained levels that exceeded safe daily intake thresholds. [Mechanism / Analytical] Thallium is a heavy metal with known cardiotoxic effects, including arrhythmia and conduction abnormalities. This is not a concern unique to hypertensive patients, but it becomes more urgent when cardiac function is already a clinical priority. Only third-party lab-tested shilajit from verified sources should be considered, particularly by anyone with cardiovascular concerns.

Frequently Asked Questions

Does shilajit lower blood pressure?

There is no human clinical trial demonstrating that shilajit lowers blood pressure in hypertensive individuals. In healthy volunteers across multiple studies, shilajit at standard doses did not significantly change blood pressure in either direction. Animal research suggests some cardioprotective effects, but these relate to myocardial protection after injury — not chronic blood pressure management. [Animal model]

Is it safe to take shilajit with blood pressure medication?

No human study has tested shilajit alongside antihypertensive drugs, so there is no direct safety data for this combination. Theoretical concerns exist around fulvic acid's chelation activity and its potential to alter mineral balance, which could interact with diuretics or other medications. Until controlled data exists, anyone on blood pressure medication should consult their prescribing physician before adding shilajit. [Mechanism]

What did the one relevant human study find?

The Stohs 2014 review in Phytother Res — the most comprehensive synthesis of human-relevant shilajit safety data — found no clinically significant cardiovascular changes (including blood pressure or heart rate) at doses of 200–500 mg per day in healthy adult populations. The Yadav 2026 RCT in Cureus similarly found no adverse blood pressure changes as a safety endpoint in physically active adults. Neither study enrolled hypertensive patients or tested concurrent antihypertensive medication use. [RCT] [Meta-analysis / Review]

Can shilajit damage the heart?

In purified, lab-tested form at appropriate doses, shilajit has not been shown to damage the heart in human studies. Joukar 2014 in Cardiovasc Toxicol actually found cardioprotective effects in a rat myocardial injury model. [Animal model] The primary cardiac risk from shilajit products is heavy metal contamination in unverified or adulterated supplements — not the compound itself. Always verify third-party testing before purchasing.

Should women with high blood pressure avoid shilajit?

Women with hypertension face the same absence-of-evidence concern as everyone else in this category, plus additional uncertainty around shilajit's hormonal effects in women. Estrogen influences blood pressure regulation, and shilajit's effects on sex hormone balance in women are not well characterized. Postmenopausal women and those on hormone therapy should seek physician guidance before use. [Anecdotal / Mechanism]

Does shilajit interact with ACE inhibitors or beta-blockers?

No published human study has examined shilajit co-administered with ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, or diuretics. There is no documented pharmacokinetic interaction data. Mechanistically, fulvic acid's chelation properties and shilajit's effects on trace mineral metabolism could theoretically affect drug absorption or electrolyte balance in patients on diuretics. This is a mechanism-based precaution, not a confirmed interaction. [Mechanism]

What dosage of shilajit is generally studied in humans?

Human studies have used doses ranging from 200 mg to 500 mg per day of purified shilajit or standardized extract. This range is where the available safety data sits. Doses above 500 mg per day have not been tested in controlled human trials, and there is no evidence that higher doses produce better cardiovascular outcomes. Stick to clinically studied ranges and choose products with verified purity documentation.

Does shilajit quality affect cardiovascular safety?

Yes, significantly. Kamgar 2025 in BMC Chem documented thallium — a cardiotoxic heavy metal — in commercial shilajit products at potentially concerning concentrations. [Mechanism / Analytical] Shilajit sourced from unverified suppliers and without independent laboratory testing carries real contamination risks that are especially relevant for anyone with cardiovascular concerns. Eurofins or equivalent third-party lab certification is a minimum standard worth insisting on.

The Bottom Line

The evidence on shilajit and blood pressure medicine reduces to this: shilajit does not appear to raise blood pressure in healthy adults at studied doses, and animal data suggest some cardiac protective properties — but there is no human RCT testing shilajit in hypertensive patients, and no safety data exists for the combination of shilajit with any antihypertensive drug class. The evidence gap is not a green light; it is an unanswered question. Anyone managing blood pressure pharmacologically should treat shilajit as they would any unstudied supplement in a cardiac context — with physician oversight and verified product quality as non-negotiable starting points.

References: Stohs 2014 (Phytother Res); Yadav 2026 (Cureus); Joukar 2014 (Cardiovasc Toxicol); Carrasco-Gallardo 2012 (Int J Alzheimers Dis); Pandit 2016 (Andrologia); Kamgar 2025 (BMC Chem).